ARGX-119

DB18133InvestigationalProtein Based Therapies

ARGX-119 is a monoclonal antibody that targets and activates muscle-specific kinase (MuSK).

Mechanism: Pharmacologically active on Muscle, skeletal receptor tyrosine-protein kinase
Curator reviewed
Also known as: a fully humanized immunoglobulin gamma 1 (IgG1) agonistic monoclonal antibody (mAb) that specifically targets and activates MuSK
Code names: ARGX-119

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with ARGX-119, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.